FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2136073528> ?p ?o ?g. }

• W2136073528 endingPage "1194" @default.
• W2136073528 startingPage "1187" @default.
• W2136073528 abstract "From bronchoprovocation studies and investigations of the acute effects of drugs that inhibit leukotrienes (LT), the hypothesis has emerged that leukotrienes are important mediators of airway obstruction and other symptoms in aspirin-intolerant asthma (AIA). However, it has yet not been shown if subjects with AIA respond favorably to clinical treatment with leukotriene inhibitors. Therefore, in a double-blind placebo-controlled crossover study, we examined the effects of 6 wk of treatment with the leukotriene-pathway inhibitor zileuton (600 mg, four times daily) in 40 patients with well-characterized AIA. The treatment was added to existing therapy, which included medium to high doses of inhaled (average daily dose 1,030 microg of beclomethasone or budesonide) or oral glucocorticosteroids (4 to 25 mg/d) for all but one of the patients. On top of this treated baseline, there were no significant effects of adding placebo, indicating that their asthma was kept relatively stable. However, there was an acute and chronic improvement in pulmonary function after treatment with zileuton, expressed both as increased FEV1 from baseline compared with placebo, and higher morning and evening peak expiratory flow rate (PEFR) values on zileuton treatment compared with placebo. The improvements occurred despite lower use of rescue bronchodilator with zileuton. Zileuton also diminished nasal dysfunction, which is one of the cardinal signs of AIA. There was a remarkable return of smell, less rhinorrhea, and a trend for less stuffiness and higher nasal inspiratory flow during treatment with zileuton. Zileuton caused a small but distinct reduction of bronchial hyperresponsiveness to histamine and inhibited aspirin-induced bronchoconstriction. Zileuton inhibited urinary excretion of LTE4 but did not change airway reactivity to inhaled LTD4, supporting that zileuton specifically inhibited leukotriene biosynthesis. The findings indicate that leukotrienes are important mediators of persistent airway obstruction and chronic nasal dysfunction in AIA. The study also suggests that addition of a leukotriene pathway inhibitor such as zileuton may bring about greater control of asthma than what is achieved by treatment with medium to high doses of glucocorticosteroids alone." @default.
• W2136073528 created "2016-06-24" @default.
• W2136073528 creator A5014449070 @default.
• W2136073528 creator A5017061318 @default.
• W2136073528 creator A5021316752 @default.
• W2136073528 creator A5027160272 @default.
• W2136073528 creator A5037141001 @default.
• W2136073528 creator A5039092503 @default.
• W2136073528 creator A5041071402 @default.
• W2136073528 creator A5056242932 @default.
• W2136073528 creator A5056829425 @default.
• W2136073528 creator A5065651957 @default.
• W2136073528 creator A5071258107 @default.
• W2136073528 creator A5082512213 @default.
• W2136073528 creator A5086617432 @default.
• W2136073528 date "1998-04-01" @default.
• W2136073528 modified "2023-10-17" @default.
• W2136073528 title "Benefits from Adding the 5-Lipoxygenase Inhibitor Zileuton to Conventional Therapy in Aspirin-intolerant Asthmatics" @default.
• W2136073528 cites W1971569966 @default.
• W2136073528 cites W1975272363 @default.
• W2136073528 cites W1978837864 @default.
• W2136073528 cites W1987062528 @default.
• W2136073528 cites W2006409700 @default.
• W2136073528 cites W2007357379 @default.
• W2136073528 cites W2009807650 @default.
• W2136073528 cites W2013221955 @default.
• W2136073528 cites W2014608611 @default.
• W2136073528 cites W2017485498 @default.
• W2136073528 cites W2019520816 @default.
• W2136073528 cites W2020767120 @default.
• W2136073528 cites W2044880620 @default.
• W2136073528 cites W2046583756 @default.
• W2136073528 cites W2063322970 @default.
• W2136073528 cites W2068619909 @default.
• W2136073528 cites W2081120829 @default.
• W2136073528 cites W2085868451 @default.
• W2136073528 cites W2091553554 @default.
• W2136073528 cites W2095871049 @default.
• W2136073528 cites W2098633046 @default.
• W2136073528 cites W2099492946 @default.
• W2136073528 cites W2104505088 @default.
• W2136073528 cites W2105573753 @default.
• W2136073528 cites W2113003679 @default.
• W2136073528 cites W2118378443 @default.
• W2136073528 cites W2138613293 @default.
• W2136073528 cites W2141574695 @default.
• W2136073528 cites W2153210153 @default.
• W2136073528 cites W2341080885 @default.
• W2136073528 cites W4229907963 @default.
• W2136073528 doi "https://doi.org/10.1164/ajrccm.157.4.9707089" @default.
• W2136073528 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9563738" @default.
• W2136073528 hasPublicationYear "1998" @default.
• W2136073528 type Work @default.
• W2136073528 sameAs 2136073528 @default.
• W2136073528 citedByCount "379" @default.
• W2136073528 countsByYear W21360735282012 @default.
• W2136073528 countsByYear W21360735282013 @default.
• W2136073528 countsByYear W21360735282014 @default.
• W2136073528 countsByYear W21360735282015 @default.
• W2136073528 countsByYear W21360735282016 @default.
• W2136073528 countsByYear W21360735282017 @default.
• W2136073528 countsByYear W21360735282018 @default.
• W2136073528 countsByYear W21360735282019 @default.
• W2136073528 countsByYear W21360735282020 @default.
• W2136073528 countsByYear W21360735282021 @default.
• W2136073528 countsByYear W21360735282022 @default.
• W2136073528 countsByYear W21360735282023 @default.
• W2136073528 crossrefType "journal-article" @default.
• W2136073528 hasAuthorship W2136073528A5014449070 @default.
• W2136073528 hasAuthorship W2136073528A5017061318 @default.
• W2136073528 hasAuthorship W2136073528A5021316752 @default.
• W2136073528 hasAuthorship W2136073528A5027160272 @default.
• W2136073528 hasAuthorship W2136073528A5037141001 @default.
• W2136073528 hasAuthorship W2136073528A5039092503 @default.
• W2136073528 hasAuthorship W2136073528A5041071402 @default.
• W2136073528 hasAuthorship W2136073528A5056242932 @default.
• W2136073528 hasAuthorship W2136073528A5056829425 @default.
• W2136073528 hasAuthorship W2136073528A5065651957 @default.
• W2136073528 hasAuthorship W2136073528A5071258107 @default.
• W2136073528 hasAuthorship W2136073528A5082512213 @default.
• W2136073528 hasAuthorship W2136073528A5086617432 @default.
• W2136073528 hasConcept C121332964 @default.
• W2136073528 hasConcept C126322002 @default.
• W2136073528 hasConcept C1276947 @default.
• W2136073528 hasConcept C142724271 @default.
• W2136073528 hasConcept C181199279 @default.
• W2136073528 hasConcept C185592680 @default.
• W2136073528 hasConcept C204787440 @default.
• W2136073528 hasConcept C27081682 @default.
• W2136073528 hasConcept C2776042228 @default.
• W2136073528 hasConcept C2776178081 @default.
• W2136073528 hasConcept C2776238763 @default.
• W2136073528 hasConcept C2776452501 @default.
• W2136073528 hasConcept C2776476923 @default.
• W2136073528 hasConcept C2777714996 @default.
• W2136073528 hasConcept C2778053663 @default.
• W2136073528 hasConcept C2778078955 @default.
• W2136073528 hasConcept C2779303165 @default.

• next